Beyond "pay-for-delay" – the EU-Commission's investigation into patent filing practices and communication measures | Allen & Overy LLP
[co-authors: On 4 March 2021, the European Commission ( Commission) opened a formal investigation into alleged anti-competitive conduct by the pharmaceutical company Teva. The Commission suspects Teva of having deployed a strategy with the intention of delaying the market entry of generic drugs that competed with Teva’s originator drug Copaxone. This may have amounted to an abuse of a dominant position prohibited under Art. 102 TFEU, the Commission states in its press release. While the Commission has sanctioned patent settlements that delay the market entry of generic drugs (“pay-for-de...